|
 |
|
< back /
08:30
|
Welcome |
Victor Huckell, MD and
Anatoly Langer, MD |
|
08:35
 |
Managing ACS Patients: Importance of dual antiplatelet therapy |
Victor Huckell, MD |
08:55
 |
How Low Do We Go and How Do We Achieve Aggressive Goals? |
Graham Wong, MD |
09:15
 |
New Insights in the Reduction of Cardiometabolic Risk |
David Fitchett, MD |
09:35
 |
Evolution of Statin Trials on Vulnerable Plaque |
Greg Bondy, MD |
09:55
 |
Innovations in Hypertension Management: Direct renin inhibition |
David Fitchett, MD |
| 10:15 |
Panel Discussion |
All Faculty |
|
| 10:45 |
Break |
|
|
11:05
 |
Management of Dyslipedemia in the Diabetic Patient |
David Miller, MD |
11:25
 |
Global CV Risk Management: Learnings from ASCOT |
John Mancini, MD |
11:45
 |
Overview of Smoking Cessation in Canada |
Richard Ward, MD |
12:05
 |
3 Minute Empowerment: How to motivate your patient to change any behaviour |
Tim O'Callahan, MD |
| 12:25 |
Panel Discussion |
All Faculty |
| 12:50 |
Lunch |
|
|
13:35
|
Better BP Control: The earlier the better |
Brett Heilbron, MD |
13:55
 |
Exploration of Landmark CV Trials: HOPE to ONTARGET |
Graham Wong, MD |
14:15
 |
Role of ACE-I: Managing risk across the CV continuum |
David Fitchett, MD |
14:35
 |
New Initiatives to Improve Care: Patient empowerment |
Anatoly Langer, MD |
14:55
|
The ABC's of ARB's for Hypertension |
Brett Heilbron, MD |
| 15:15 |
Panel Discussion |
All Faculty |
|
| 15:45 |
Close |
|
|
|
 |
|